Table 2.

PCR results associated with microscopy findings and clinical characteristics

Patient	Species	No. days since treatment	Microscopy (parasite%)	PCR	Fever duration before treatment (days)	Treatment	Origin/years out of endemic area	Comorbidity
No. 1	P.f + P.m	0	Pos (2)	Pos	35	AL	SSA/1	HIV
		1	Pos (1)	Posb,c
No. 2	P.f	0	Pos (4)	Pos	2	A, AL	SSA/8	HIV
		1	Pos (4)	Posb,c
No. 3	P.f	0	Pos (12)		3	A, AP	Norway
		1	Neg	Pos
		2	Neg	Pos
		11	Neg	Posb
No. 4	P.f	0	Pos (< 1)a		38	AP	SSA/10
		31	Neg	Neg
No. 5	P.f	0	Pos (< 1)		7	AL	SSA/46
		32	Neg	Pos
No. 6	P.f	0	Pos (2)	Pos	9	Q, A, AL	SSA/21
		1	Pos (< 0.5)	Posb,c
		37	Neg	Pos
No. 7	P.f	0	Pos (10)	Pos	21	A, AL	SSA/10	HIV
		4	Neg	Pos
		11	Neg	Pos
		39	Neg	Neg
No. 8	P.f	0	Pos (30)	Pos	3	A,	Norway
		1	Pos (6)	Posb,c		Erythrocyte
		45	Neg	Pos		apheresis, AL
No. 9	P.f	0	Pos (6)a		13	A, AP, AL	SSA/17	Sickle cell disease
		49	Neg	Pos
No.10	P.v	0	Pos (0.5)		10	AP, P	SEA/30
		2	Posa	Posb,c
No. 11	P.v	0	Pos (0.5)a		Not known	AP, P	SSA
		6	Neg	Pos
No. 12	P.v	0	Pos	Pos	2	A, AP, P	Norway
		23	Neg	Neg
No. 13	P.v	0	Pos		6	C, P	Norway
		54	Neg	Neg

AL artemether-lumefantrine, A artesunate IV (intravenous), PA atovaquone-proguanil, Q quinine IV, C chloroquine, P primaquine, HIV human immunodeficiency virus, SSA sub-Saharan Africa, SEA Southeast Asia

^aGametocytes seen by microscopy

^bDetection of 18S mRNA transcripts (Produced by all parasite stages)

^cDetection of gametocyte-specific mRNA